You are here: Industry Insights > IPS

News List

R&D Alliance for Eye Disease Cell Therapies contractpharma
May 18, 2021
BlueRock Therapeutics, Fujifilm Cellular Dynamics, and Opsis Therapeutics enter R&D pact to discover and develop cell therapies for eye diseases.
8-10 months protection possible with COVID-19 vaccine: AIIMS director expresspharma
March 22, 2021
He said the biggest reason for the surge in cases is that people feel the pandemic is over and they are not following COVID-appropriate behaviour.
Cell and Gene Therapy Catapult links with Japan's CiRA Foundation pharmatimes
May 14, 2020
The Cell and Gene Therapy Catapult (CGT Catapult) and Kyoto, Japan-based CiRA Foundation are launching a new collaborative research project focused on induced pluripotent stem (iPS) cell characterisation.
Metrohm acquires innovative Photonic Solutions to expand Handheld Raman portfolio europeanpharmaceuticalreview
April 29, 2019
Metrohm acquires innovative Photonic Solutions to expand Handheld Raman portfolio
Thyas Obtains Exclusive Rights to Manufacture Induced Pluripotent Stem Cells-Derived Killer T Cells for Autologous Immunotherapy pharmafocusasia
January 21, 2019
Thyas Co. Ltd. (Thyas) signed a licensing agreement with iPS Academia Japan, Inc. (iPS-AJ), a technology licensing organization of induced pluripotent stem (iPS) cell related-patents from Kyoto University.....
Scientists devise breakthrough therapy for Parkinson’s biospectrumasia
September 05, 2017
Japanese researchers have shown that human induced pluripotent stem cells (iPS) can be administered safely and effectively to treat primates with symptoms of the debilitating disease.
IPS Expands Leadership Team contractpharma
June 06, 2017
Integrated Project Services (IPS) has appointed Mark Butler to president, managing director of the Americas unit.